Pseudohypoparathyroidism
Disease Details
Family Health Simplified
- Description
- Pseudohypoparathyroidism is a genetic disorder characterized by the body's resistance to parathyroid hormone, leading to low calcium and high phosphate levels in the blood despite normal or elevated levels of the hormone.
- Type
- Pseudohypoparathyroidism is primarily inherited in an autosomal dominant manner. This means that only one copy of the altered gene inherited from an affected parent is necessary to cause the disorder.
- Signs And Symptoms
-
Pseudohypoparathyroidism is a rare inherited disorder characterized by the body's resistance to the parathyroid hormone (PTH), which regulates calcium and phosphate levels.
Signs and symptoms typically include:
- Short stature and a stocky build
- Round face and short neck
- Shortened fourth and fifth metacarpals (knuckles)
- Developmental delays or intellectual disability
- Dental abnormalities
- Subcutaneous (under the skin) calcifications (calcium deposits)
Patients may also experience symptoms related to low calcium levels, such as muscle cramps or spasms (tetany), numbness, and tingling in the extremities.
If you have specific questions or need detailed information, please provide additional context. - Prognosis
- Pseudohypoparathyroidism is a genetic disorder characterized by the body's resistance to parathyroid hormone, leading to low calcium and high phosphate levels in the blood. The prognosis for individuals with pseudohypoparathyroidism is generally good with proper management of the condition, including calcium and vitamin D supplementation to maintain appropriate mineral balance. However, the long-term outlook can vary depending on the subtype and severity of the disorder, as well as the presence of any associated complications such as developmental delays or physical abnormalities. Regular monitoring and medical care are essential to manage symptoms and prevent complications.
- Onset
- Pseudohypoparathyroidism typically has its onset in childhood.
- Prevalence
- The prevalence of pseudohypoparathyroidism is estimated to be around 1 in 100,000 to 1 in 200,000 individuals.
- Epidemiology
- Pseudohypoparathyroidism (PHP) is a rare genetic disorder characterized by resistance to the parathyroid hormone (PTH), leading to low calcium levels and high phosphate levels in the blood. The prevalence of PHP varies, but it is estimated to occur in approximately 0.79 to 1.1 per 100,000 people. The condition affects both males and females equally and manifests in various forms, the most common being PHP type 1a, which is associated with Albright hereditary osteodystrophy (AHO). This disorder has an autosomal dominant inheritance pattern, meaning it can be passed from an affected parent to their child with a 50% chance.
- Intractability
- Pseudohypoparathyroidism is not considered intractable. It is a genetic disorder characterized by the body's resistance to parathyroid hormone (PTH), which can lead to low calcium levels and high phosphate levels in the blood. The condition can typically be managed with proper medical treatment, including supplementation of calcium and active forms of vitamin D, along with regular monitoring and supportive care. While it is a chronic condition requiring ongoing management, it is not usually labeled as intractable.
- Disease Severity
-
Pseudohypoparathyroidism is a rare genetic disorder characterized by the body's resistance to the parathyroid hormone, which is crucial for regulating calcium and phosphate levels. The disease severity can vary, but common symptoms include hypocalcemia (low calcium levels), hyperphosphatemia (high phosphate levels), and associated symptoms like muscle cramps, spasms, and potentially seizures. Long-term complications may include issues with bone density and development, as well as cognitive impairment.
As for the nan (not a number) aspect, if you're referring to quantitative measures of disease severity, pseudohypoparathyroidism does not typically have a numerical score to represent its severity; rather, it is assessed based on clinical symptoms and biochemical findings. - Healthcare Professionals
- Disease Ontology ID - DOID:4184
- Pathophysiology
- Pseudohypoparathyroidism is a condition characterized by resistance to the parathyroid hormone (PTH). Despite normal or elevated levels of PTH, target tissues (such as the kidneys and bones) do not respond appropriately, leading to hypocalcemia (low serum calcium levels) and hyperphosphatemia (elevated serum phosphate levels). This resistance is often due to genetic mutations affecting the GNAS gene, which encodes the Gs alpha subunit involved in PTH signal transduction. As a result, the downstream effects of PTH are blunted, disrupting calcium and phosphate homeostasis.
- Carrier Status
- Pseudohypoparathyroidism is not typically associated with a simple carrier status because it usually follows an autosomal dominant inheritance pattern with variable expression. This means that if one parent has the condition, there is a 50% chance of passing the affected gene to their offspring. Carriers in the traditional sense (as seen in recessive disorders) are not typically discussed for this condition.
- Mechanism
-
Pseudohypoparathyroidism is a condition characterized by resistance to the parathyroid hormone (PTH), leading to low calcium levels and high phosphate levels in the blood.
**Mechanism:**
The primary mechanism involves the body's inability to respond to PTH. Although PTH levels may be normal or elevated, the kidneys and bones do not respond to it properly, resulting in the clinical manifestations of hypoparathyroidism, such as hypocalcemia and hyperphosphatemia.
**Molecular Mechanisms:**
1. **GNAS Gene Mutation**: The most common cause of pseudohypoparathyroidism is a mutation in the GNAS gene, which encodes the alpha subunit of the stimulatory G protein (Gsα). This protein is crucial for the signal transduction pathway of PTH.
2. **Impaired G Protein-Coupled Receptor Signaling**: Mutations in the GNAS gene affect the G protein-coupled receptor (GPCR) signaling, impairing the activation of adenylate cyclase and reducing cyclic AMP (cAMP) production. This leads to decreased cellular responses to PTH, particularly in the renal tubules.
3. **Epigenetic Changes**: In some cases, epigenetic modifications, such as methylation changes at the GNAS locus, can also contribute to the disease by impairing the expression of Gsα or related regulatory proteins.
Overall, the disrupted G protein signaling results in the failure of target organs to respond adequately to PTH, thereby causing the characteristic biochemical abnormalities seen in pseudohypoparathyroidism. - Treatment
- Calcium and Calcitriol supplements, the latter with a larger dose than for treatment of hypoparathyroidism.
- Compassionate Use Treatment
-
For pseudohypoparathyroidism, compassionate use treatment, off-label, or experimental treatments may include:
1. **PTH (1-34) or Teriparatide**: While not typically approved for this condition, synthetic parathyroid hormone analogs like Teriparatide have been explored for their potential to manage symptoms by directly addressing the underlying hormone deficiency.
2. **Calcitriol and Calcium Supplements**: Though not experimental, aggressive management with active forms of Vitamin D (like Calcitriol) and calcium may be used in more innovative or personalized treatment approaches.
3. **Phosphate Binders**: In cases of hyperphosphatemia, these may be implemented off-label to carefully manage phosphate levels, indirectly helping correct symptoms associated with the disease.
4. **Magnesium Supplements**: Sometimes used in experimental contexts, as magnesium plays a role in parathyroid hormone function and calcium balance.
These treatments are highly dependent on individual patient circumstances and ongoing research, and should be considered with specialist guidance. - Lifestyle Recommendations
-
Lifestyle recommendations for managing pseudohypoparathyroidism typically focus on ensuring adequate calcium and vitamin D intake and monitoring overall health. Here are some key recommendations:
1. **Dietary Management:**
- **Calcium-Rich Foods:** Incorporate foods high in calcium, such as dairy products, leafy greens, almonds, and fortified foods.
- **Vitamin D:** Ensure adequate vitamin D intake through sunlight exposure, diet (e.g., fatty fish, fortified foods), and supplements if needed.
2. **Regular Monitoring:**
- Regular blood tests to monitor calcium and phosphate levels.
- Periodic check-ups with a healthcare provider to adjust treatment as necessary.
3. **Physical Activity:**
- Engage in regular, weight-bearing exercises to strengthen bones and improve overall health.
- Ensure proper hydration and balanced nutrition to support physical activity.
4. **Medication Adherence:**
- Follow prescribed medication regimens closely, including calcium and vitamin D supplements.
5. **Education and Awareness:**
- Educate yourself and family members about the condition to understand symptoms and management strategies.
- Attend patient support groups for additional guidance and emotional support.
6. **Avoiding Triggers:**
- Stay away from factors that can exacerbate symptoms, such as excessive phosphorus intake (found in processed foods and soft drinks).
7. **Regular Eye and Dental Exams:**
- Stay vigilant about eye health and dental care, as the condition can affect these areas.
These lifestyle modifications can help manage symptoms and improve the quality of life for those with pseudohypoparathyroidism. - Medication
- Pseudohypoparathyroidism is typically managed with calcium supplements and active forms of vitamin D, such as calcitriol. These help to maintain normal calcium levels in the blood. In some cases, phosphate binders may be used to control high phosphate levels. Since pseudohypoparathyroidism can vary in severity, treatment plans should be individualized and regularly monitored by healthcare providers.
- Repurposable Drugs
-
There are no widely recognized or established repurposable drugs specifically for pseudohypoparathyroidism at present. The condition is primarily managed through conventional therapies aimed at addressing its symptoms and underlying biochemical abnormalities, such as calcium and phosphate metabolism.
Treatment often includes:
- Calcium supplements
- Active forms of vitamin D (like calcitriol)
For more personalized treatments and emerging therapies, consultation with a healthcare professional or referring to recent medical literature is advisable. - Metabolites
-
Pseudohypoparathyroidism is a disorder characterized by the body's resistance to the parathyroid hormone (PTH), despite having normal or elevated levels of this hormone. Key metabolites involved in this condition include:
1. **Serum Calcium**: Often low due to the resistance to PTH, impairing calcium absorption in kidneys and intestines.
2. **Serum Phosphate**: Typically elevated because PTH resistance decreases phosphate excretion.
3. **cAMP (Cyclic Adenosine Monophosphate)**: Urinary cAMP levels may be low following administration of exogenous PTH, reflecting impaired signaling.
4. **Serum PTH**: Usually elevated as the parathyroid glands overcompensate for the perceived deficiency in PTH activity.
These abnormal metabolite levels help in diagnosing and understanding the biochemical profile of pseudohypoparathyroidism. - Nutraceuticals
- Pseudohypoparathyroidism is a genetic disorder characterized by the body's resistance to the parathyroid hormone (PTH), resulting in low calcium and high phosphate levels in the blood. As for nutraceuticals, there is no conclusive evidence that specific nutraceuticals can effectively treat or manage pseudohypoparathyroidism. Management typically involves conventional treatments such as calcium and active vitamin D supplements to maintain normal calcium levels in the blood. Always consult a healthcare provider for treatment options tailored to individual cases.
- Peptides
- Pseudohypoparathyroidism is a genetic disorder characterized by resistance to parathyroid hormone (PTH). Despite normal or elevated levels of PTH, the body cannot properly respond to it, leading to low calcium and high phosphate levels in the blood. It is often associated with mutations in the GNAS gene, which affects the signaling pathways involved in PTH response. Symptoms can include short stature, obesity, round face, dental issues, and skeletal abnormalities. The condition often requires management of calcium and phosphate levels through supplements and medications.